The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance.

Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases.

http://ift.tt/2fbo2a8